SG11201403771SA - New c5a binding nucleic acids - Google Patents

New c5a binding nucleic acids

Info

Publication number
SG11201403771SA
SG11201403771SA SG11201403771SA SG11201403771SA SG11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA
Authority
SG
Singapore
Prior art keywords
new
nucleic acids
binding nucleic
binding
acids
Prior art date
Application number
SG11201403771SA
Other languages
English (en)
Inventor
Kai Höhlig
Axel Vater
Klaus Buchner
Christian Maasch
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/fr
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of SG11201403771SA publication Critical patent/SG11201403771SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
SG11201403771SA 2012-01-10 2013-01-10 New c5a binding nucleic acids SG11201403771SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2012/000089 WO2012095303A1 (fr) 2011-01-10 2012-01-10 Molécule d'acide nucléique ayant une affinité de liaison vis-à-vis d'une molécule cible et son procédé de génération
EP12000106 2012-01-10
EP12006960 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (fr) 2012-01-10 2013-01-10 Nouveaux acides nucléiques de liaison c5a

Publications (1)

Publication Number Publication Date
SG11201403771SA true SG11201403771SA (en) 2014-07-30

Family

ID=48781063

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403771SA SG11201403771SA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids
SG10201605594UA SG10201605594UA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201605594UA SG10201605594UA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Country Status (19)

Country Link
US (3) US9518265B2 (fr)
EP (1) EP2802660B1 (fr)
JP (1) JP6415327B2 (fr)
KR (1) KR102034203B1 (fr)
CN (1) CN104145018B (fr)
AU (2) AU2013209131A1 (fr)
BR (1) BR112014016877B1 (fr)
CA (1) CA2860806C (fr)
DK (1) DK2802660T3 (fr)
ES (1) ES2786007T3 (fr)
HK (1) HK1198371A1 (fr)
IL (1) IL233516B (fr)
IN (1) IN2014DN05665A (fr)
MX (1) MX362061B (fr)
PL (1) PL2802660T3 (fr)
PT (1) PT2802660T (fr)
RU (1) RU2645261C2 (fr)
SG (2) SG11201403771SA (fr)
WO (1) WO2013104540A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849323A (zh) 2013-10-28 2016-08-10 多茨设备公司 过敏原检测
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
EP3793427A1 (fr) 2018-05-17 2021-03-24 The Procter & Gamble Company Systèmes et procédés d'analyse de la couvrance des cheveux
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
EP3586865A1 (fr) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Liants d'anaphylatoxine de complément et leur utilisation dans le traitement d'un sujet présentant une plaie oculaire et/ou une fibrose
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
KR20210113173A (ko) * 2018-11-12 2021-09-15 아프타리온 바이오테크 아게 Cxcl8 결합 핵산
EP3956451A1 (fr) 2019-04-16 2022-02-23 The Procter & Gamble Company Aptamères pour applications de contrôle des odeurs
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1438321B1 (fr) 2001-10-26 2010-05-26 Noxxon Pharma AG Acide l-nucleique modifie
EP1306382A1 (fr) 2001-10-26 2003-05-02 Noxxon Pharma AG L-acides nucléiques modifiés
WO2003070823A2 (fr) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugues contenant un polymere biodegradable, et leurs utilisations
EP1620450A4 (fr) 2003-04-13 2011-01-19 Enzon Pharmaceuticals Inc Promedicaments oligonucleotidiques polymeres
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
HUE050481T2 (hu) * 2004-02-12 2020-12-28 Archemix Llc Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
WO2005099768A2 (fr) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Lieur de promedicaments
CA2585664C (fr) 2004-11-05 2014-05-20 The Children's Hospital Of Philadelphia Linkers biodegradables pour therapies moleculaires
JP2008526915A (ja) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト Ｃ５ａ受容体アンタゴニスト
SI2596807T1 (sl) 2006-03-08 2016-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
WO2008034122A2 (fr) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides
EP2407558A1 (fr) 2006-10-31 2012-01-18 Noxxon Pharma AG Procédés de détection d'une molécule d'acide nucléique à double ou simple brin
RU2010116245A (ru) * 2007-09-24 2011-11-10 Ноксон Фарма Аг (De) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
WO2010103868A1 (fr) 2009-03-11 2010-09-16 オリンパスメディカルシステムズ株式会社 Système de traitement d'image, dispositif externe afférent et procédé de traitement d'image afférent
US20120065254A1 (en) 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
US8871920B2 (en) 2010-04-21 2014-10-28 Noxxon Pharma Ag Lipid binding nucleic acids
EP2663640B1 (fr) * 2011-01-10 2020-11-04 APTARION biotech AG Molécule d'acide nucléique ayant une affinité de liaison vis-à-vis d'une molécule cible et son procédé de génération
JP2014533098A (ja) 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
MX2014008456A (es) 2012-01-10 2014-11-25 Noxxon Pharma Ag Acidos nucleicos que enlazan especificamente a cgrp.

Also Published As

Publication number Publication date
CA2860806C (fr) 2020-10-20
HK1198371A1 (en) 2015-04-10
ES2786007T3 (es) 2020-10-08
IN2014DN05665A (fr) 2015-05-15
PT2802660T (pt) 2020-04-21
JP6415327B2 (ja) 2018-10-31
CA2860806A1 (fr) 2013-07-18
IL233516B (en) 2018-07-31
MX362061B (es) 2019-01-07
SG10201605594UA (en) 2016-09-29
JP2015509705A (ja) 2015-04-02
US20140364487A1 (en) 2014-12-11
CN104145018A (zh) 2014-11-12
BR112014016877B1 (pt) 2022-03-15
MX2014008454A (es) 2015-02-05
BR112014016877A2 (pt) 2019-10-29
PL2802660T3 (pl) 2020-07-27
AU2018271388A1 (en) 2018-12-20
IL233516A0 (en) 2014-08-31
EP2802660A1 (fr) 2014-11-19
EP2802660B1 (fr) 2020-02-19
AU2018271388B2 (en) 2021-03-11
RU2014132708A (ru) 2016-02-27
US10590424B2 (en) 2020-03-17
CN104145018B (zh) 2019-05-10
KR102034203B1 (ko) 2019-10-18
US20210163946A1 (en) 2021-06-03
US9518265B2 (en) 2016-12-13
US20180223285A1 (en) 2018-08-09
WO2013104540A1 (fr) 2013-07-18
DK2802660T3 (da) 2020-05-18
RU2645261C2 (ru) 2018-02-19
AU2013209131A1 (en) 2014-07-10
KR20140111703A (ko) 2014-09-19
US11492625B2 (en) 2022-11-08

Similar Documents

Publication Publication Date Title
HK1209162A1 (zh) 條形編碼核酸
DK2922554T3 (en) Terminalt modificeret rna
IL231983A0 (en) Dna containing tricyclo-phosphorothioate
AP2015008266A0 (en) 1L-18 binding molecules
IL235325A0 (en) Nucleic acid extraction
EP2859111A4 (fr) Amplifications d'acide nucléique
EP2694683A4 (fr) ACIDES NUCLÉIQUES GAMMA-PEPTIDIQUES CONTENANT DU MiniPEG, CONFORMATIONNELLEMENT PRÉORGANISÉS
HK1198371A1 (en) New c5a binding nucleic acids c5a
GB2506862B (en) Book
GB201204407D0 (en) Nucleic acid molecule
PL2928935T3 (pl) Środki wiążące
EP2902488A4 (fr) Adn polymérase modifiée
EP2915815A4 (fr) Acide nucléique modifié inédit
HK1198370A1 (en) Nucleic acids specifically binding cgrp cgrp
PL2928936T3 (pl) Spoiwo
IL231980A0 (en) Glucagon binding nucleic acids
GB2501157B (en) Space heater
EP2844772A4 (fr) Séquençage d'adn
EP2868485A4 (fr) Classeur
EP2975121A4 (fr) Séquence de liaison d'acide nucléique
EP2817419A4 (fr) Identificateur d'adn chimérique
EP2844775A4 (fr) Séquençage d'adn
EP2814969A4 (fr) Assimiliation de l'adn
EP2831277A4 (fr) Acides nucléiques click
GB201201849D0 (en) Space heater